Healthcare Industry News: Cyclacel Pharmaceuticals
News Release - June 27, 2007
Cyclacel Pharmaceuticals Announces Appointment of Distinguished Pharma Executive as Senior Vice President, ResearchBERKELEY HEIGHTS, N.J.--(HSMN NewsFeed)--Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today that Gregory R. Reyes, M.D., Ph.D. has joined the company as Senior Vice President, Research. Dr. Reyes has more than 22 years of experience in leadership roles at a number of biotechnology and pharmaceutical companies including Schering-Plough and, most recently, Pfizer, where he served as Vice President, Biology, Discovery Research, within Pfizer Global Research & Development.
During his tenure at Pfizer Global Research & Development's Ann Arbor site, Dr. Reyes had responsibility for delivering the annual contribution of new chemical entities and biotherapeutics from the site. He supervised several hundred employees working in multiple therapeutic areas. Dr. Reyes was a member of Pfizer's global discovery research management teams which were responsible for the development and implementation of Pfizer's worldwide discovery research strategy. Before Pfizer, Dr. Reyes served as Vice President, Biological Research, Infectious Diseases and Tumor Biology at Schering-Plough Research Institute (SPRI) and was a member of SPRI's Executive Committee. At Schering-Plough, where he supervised approximately two hundred scientists, his primary responsibilities included setting strategic direction, priorities, and ongoing review of drug discovery programs in oncology and anti-infectives resulting in 14 new drug candidates progressing into preclinical and clinical development. Prior to Schering-Plough Dr. Reyes served as Vice President, Research and Development at Ingenex, Inc., Vice President, Molecular and Biological Research at Triplex Pharmaceuticals, Inc. and Vice President, Hepatitis Research at GeneLabs, Inc. where he pursued multiple oncology and antiviral programs from discovery to clinical trials.
Dr. Reyes earned his B.A. summa cum laude in Biology from the University of California at Santa Cruz in 1976, his M.D. and Ph.D. from The Johns Hopkins School of Medicine in 1982, completed his internship at Stanford University Hospital in 1983 and was Damon Runyon-Walter Winchell Cancer Fund Postdoctoral Fellow at Stanford University Hospital. He has received numerous awards and distinctions and was recently appointed by the Director of the National Institutes of Health (NIH) to the National Advisory General Medical Sciences Council for a four year term ending in December 2007.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Two Cyclacel drugs are in Phase II trials: sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, for the treatment of cutaneous T-cell lymphoma (CTCL) and seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, for the treatment of lung cancer. Sapacitabine is also in Phase I trials in patients with hematologic malignancies. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is at the IND stage. Several additional programs are at an earlier stage.
Please visit http://www.cyclacel.com/cyc/investors/news/pressreleases for additional information.
Note: The Cyclacel logo and CyclacelŽ are trademarks of Cyclacel Pharmaceuticals, Inc.
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Forms 10-K and in the other reports of Cyclacel filed with the SEC.
Source: Cyclacel Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.